{"name":"Beijing Pearl Biotechnology Limited Liability Company","slug":"beijing-pearl-biotechnology-limited-liability-company","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PLB1001","genericName":"PLB1001","slug":"plb1001","indication":"Acute myeloid leukemia (AML)","status":"phase_3"}]}],"pipeline":[{"name":"PLB1001","genericName":"PLB1001","slug":"plb1001","phase":"phase_3","mechanism":"PLB1001 is a small-molecule inhibitor that targets specific kinases involved in cancer cell proliferation and survival.","indications":["Acute myeloid leukemia (AML)","Other hematologic malignancies"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQdkRiZW1wLWJfVlVZQW0xeUlTOUJiRHZZdkYzZzhuM2tHbHNTWm5Ca2hOU0kxaGw4YWx3ck14SkluOGI0NWJSdFhDa3o3R0tEbU5SanFfZGVTVTJjVktlRjhGWDlQdHBpR2ZEemotUEdKa2VDazhlVl9BUThZYTQ0aVh6S2haak5Mbng2dW1SVGF1LWkteHlPWG5pZHJSR25IMDFwUWtWYzZRdnlWMDV1Tk8yY01BbFhGbjV0ZmRWbU51ektCU2NDRXFKenFEeWRZUlZIanBmZHphYnhtVXZWUGpfTE9lbVVlcXJQVDRR?oc=5","date":"2026-03-26","type":"trial","source":"Barchart.com","summary":"ALK Inhibitors Clinical Trial Pipeline Expands as 15+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com","headline":"ALK Inhibitors Clinical Trial Pipeline Expands as 15+ Companies Driving Innovation in the Therapeutics | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOMEVheldSaklNV3NPQlUxWG1wTUxtUGhVNi11UGhpWkM5UURlZmdnZjdLRVVKZDNFNkNWdkxSaGp1aW1UYWZGMlBiS09qbndncFJNLWNJcXZXOVpncUFwNTFFLTFHUGRnMGE2V0ZkSWFPb2liNWg4eFlWYkZwWmxWeXRsUkVYUEF6ekhXSHFYazZiOGhwSDhEWmsyZG8?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"c-MET-NSCLC Clinical Trial Pipeline Accelerates as 25+ Pharma - openPR.com","headline":"c-MET-NSCLC Clinical Trial Pipeline Accelerates as 25+ Pharma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOWi1mY3E1LXBUaC1XMURMYl9uOWg3dFRtZjJDWDlhZXIzbFpaS1FETjdETHlXdW9mbEd0SlpNb0ViN2M1LUdRbzdCSWRkYkhiYzB4VjBDbnp5ZlZZTElMcUNSMG12Sk5RMEFmTGRKelVRNUttQmZnSU5xaXE4Q1RvalZVRzNnQQ?oc=5","date":"2025-10-28","type":"pipeline","source":"Labiotech.eu","summary":"10 biotech companies in China you should know about - Labiotech.eu","headline":"10 biotech companies in China you should know about","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxPTVgxRjY3d3JSY2hpMjVzLURucDBDeTBFd2NDLWFXT3U2dkFGQU9YYnB5QUd1Njd2WFBMdTN5NklPMGVSNGxZa1VZQmotTUxkTTlXeHBGd1V3X0wycElWS05jV0VBRXotTloza0EtdUpHVmRmUUVZRzlfZGtnWVFYd1VIYlNJR28yOGxpUEZuNEFzODdLTVQzOWNaNnpjcXlfdEF6UUJ4bDdfbHFQbDZNOFhpYjAtRWxQWUVaeDV0SFo1OWc0Q0t4MDQ1cFd3d3c3OW45ejdadnc0Z0swMFN5R0Q3R2hDcUxKNWhBVU14TFJkdw?oc=5","date":"2025-03-06","type":"pipeline","source":"prnewswire.com","summary":"TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping NSCLC Therapy | DelveInsight - prnewswire.com","headline":"TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping NSCLC Therapy | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPY3Jid1plRGVlOGJnUVBIVnNaMEdTLTkyNHUtcndJZXgtY1FtN3MxRnZnenlFaGUwcjNuc1VVUnNZaGd6S2JPUk9HdkIyeFN6UGw2NFVLSFV5eVNrS3RRV1NENURFTFF1NUt6d0x0X0xHMzVza0JoMk9TTHJWOFNuVjJULWlKLUREN3c?oc=5","date":"2017-12-04","type":"pipeline","source":"BioSpace","summary":"What You Need to Know About CBT Pharmaceuticals - BioSpace","headline":"What You Need to Know About CBT Pharmaceuticals","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}